
Aerie Pharmaceuticals (NASDAQ: AERI)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Aerie Pharmaceuticals Returns vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Aerie Pharmaceuticals Company Info
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company engaged in the discovery development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
News & Analysis
You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Success in clinical trials doesn't guarantee success on the market.
The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.
A new slide deck shows reasons for optimism.
Valuation
Earnings Transcripts
AERI earnings call for the period ending September 30, 2021.
AERI earnings call for the period ending June 30, 2021.
AERI earnings call for the period ending September 30, 2020.
AERI earnings call for the period ending June 30, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.